DB Power and LPA announce strategic partnership to globally expand solutions for issuers of structured retail products

Real Time Search
CES A80 :
CES HKMI :
CES 120 :
Total Turn.

03759 PHARMARON

Trading Add to Porfolio
Index Constituent : None
Major Shareholders Shenzhen Xinzhong Kangcheng Investment Partnership (Limited Partnership) (14.73%)
LOU Boliang & Associates (10.19%)
ZHENG Bei & Associates (8.06%)		 Sector Health Care & Biotechnology
Web Site http://www.pharmaron.com Tel (86 10) 5733-0087
Email pharmaron@pharmaron.com Fax N/A
Related Equities N/A
Principal Activities The principal activity of the Group is to provide contract research, development and manufacturing services for innovative pharmaceutical products throughout the research and development cycle and the services are organised in four major categories: laboratory services, CMC (small molecule CDMO) services, clinical development services, and biologics and CGT services.

Consolidated List of Substantial Shareholders

Name Number of Shares Interested % of Issued Share Capital (%) Date of Last Notice Filed (Y/M/D)
Last Update :
Note : (L) - Long Position (S) - Short Position (P) - Lending Pool

Complete List of Directors

Director's Name Number of Shares Interested % of issued share capital (%) Date of Last Notice Filed (Y/M/D)
Last Update :
Note : (L) - Long Position (S) - Short Position (P) - Lending Pool
Back to Top